eosinofile-leukocytter (LH Indholdsside)

<Provider Id="sundheddkcms">
  <Item Id="{E445BBA6-BF43-4931-969D-73B954AED19E}" Name="eosinofile-leukocytter" Type="LHContentPage" ParentProviderId="sundheddkcms" ParentItemId="{954990FB-BCA1-4322-A1A9-62D3FD4B2E07}" SortOrder="3500" PublishDate="2010-10-08T10:48:00" DeleteDate="2999-12-31T00:00:00" PotItemType="">
    <Content>
      <HtmlField Name="PageContent"><![CDATA[<h2>Definition</h2>
<ul>
    <li>Antallet af eosinofile leukocytter i blodet, m&aring;lt som milliarder celler per liter, dvs. som 10<sup>9</sup>/L, eller angivet i procent af det <a href="~/link.aspx?_id=6CDE4862E4E447FD854B74893DD46443&amp;_z=z">totale leukocyttal</a>&nbsp;</li>
    <li>Navnet skyldes udseendet af cellerne i et farvet blodudstrygningspr&aelig;parat, hvor deres store cytoplasmatiske granulae er oranger&oslash;de. Granulae indeholder forskellige cytokiner og cytotoksiske enzymer og proteiner</li>
</ul>
<h2>Synonymer</h2>
<ul>
    <li>Eosinofilocytter; eosinofile granulocytter</li>
</ul>
<h2>Indikationer</h2>
<ul>
    <li>Analysen kan ikke bestilles separat, men svares som en del af resultatet af en differentialt&aelig;lling af leukocytterne (leukocyttyper)</li>
    <li>Eosinofil-antallet er s&aelig;rligt relevant ved mistanke om<a href="EditorPage.aspx?da=core&amp;id=%7BE445BBA6-BF43-4931-969D-73B954AED19E%7D&amp;ed=FIELD28113310743&amp;vs&amp;la=da&amp;fld=%7B850D32D3-55A1-49E4-9CDF-F0C88D91563C%7D&amp;so=%2Fsitecore%2Fsystem%2FSettings%2FHtml%20Editor%20Profiles%2FRich%20Text%20LHPH&amp;di=0&amp;hdl=H28113310802&amp;us=sitecore%5Cneho&amp;mo&amp;pe=0&amp;fbd=1" data-type="book-reference" data-value="Lyngbye J, Kjær A, Ladefoged SA, Nissen PH. Lyngbyes laboratoriemedicin. 2. udg. København: Nyt Nordisk Forlag Arnold Busck A/S; 2010" data-value-piped="Lyngbye J, Kjær A, Ladefoged SA, Nissen PH|Lyngbyes laboratoriemedicin. 2. udg|København|Nyt Nordisk Forlag Arnold Busck A/S|2010" data-url="reference-link" title="Lyngbye J, Kjær A, Ladefoged SA, Nissen PH. Lyngbyes laboratoriemedicin. 2. udg. København: Nyt Nordisk Forlag Arnold Busck A/S; 2010"><sup>1</sup></a>
    <ul>
        <li>Allergiske sygdomme</li>
        <li>Parasit&aelig;re infektioner</li>
        <li>Autoimmune sygdomme</li>
        <li>Vaskulitter</li>
        <li>Visse maligne sygdomme</li>
    </ul>
    </li>
</ul>
<h2>Fortolkninger</h2>
<h3>Forh&oslash;jede v&aelig;rdier (eosinofili)<a href="EditorPage.aspx?da=core&amp;id=%7BE445BBA6-BF43-4931-969D-73B954AED19E%7D&amp;ed=FIELD27460889023&amp;vs&amp;la=da&amp;fld=%7B850D32D3-55A1-49E4-9CDF-F0C88D91563C%7D&amp;so=%2Fsitecore%2Fsystem%2FSettings%2FHtml%20Editor%20Profiles%2FRich%20Text%20LHPH&amp;di=0&amp;hdl=H27460889125&amp;us=sitecore%5Canvi&amp;mo&amp;pe=0&amp;fbd=1" data-type="journal-reference" data-value="Khoury P, Bochner BS, Consultation for Elevated Blood Eosinophils: Clinical Presentations, High Value Diagnostic Tests, and Treatment Options. J Allergy Clin Immunol Pract 2018;6: 1446-1453" data-value-piped="Khoury P, Bochner BS|Consultation for Elevated Blood Eosinophils: Clinical Presentations, High Value Diagnostic Tests, and Treatment Options.|J Allergy Clin Immunol Pract|2018|6|1446-1453|30197068" data-url="reference-link" data-pubmedid="30197068" title="Khoury P, Bochner BS, Consultation for Elevated Blood Eosinophils: Clinical Presentations, High Value Diagnostic Tests, and Treatment Options. J Allergy Clin Immunol Pract 2018;6: 1446-1453"><sup>2</sup></a><sup>,</sup><a href=" " data-type="journal-reference" data-value="Kuang FL, Approach to Patients with Eosinophilia. Med Clin North Am 2020;104: 1-14" data-value-piped="Kuang FL|Approach to Patients with Eosinophilia.|Med Clin North Am|2020|104|1-14|31757229" data-url="reference-link" data-pubmedid="31757229" title="Kuang FL, Approach to Patients with Eosinophilia. Med Clin North Am 2020;104: 1-14"><sup>3</sup></a><sup>,</sup><a href=" " data-type="journal-reference" data-value="Cottin V, Eosinophilic Lung Diseases. Immunol Allergy Clin North Am 2023;43: 289-322" data-value-piped="Cottin V|Eosinophilic Lung Diseases.|Immunol Allergy Clin North Am|2023|43|289-322|37055090" data-url="reference-link" data-pubmedid="37055090" title="Cottin V, Eosinophilic Lung Diseases. Immunol Allergy Clin North Am 2023;43: 289-322"><sup>4</sup></a><sup>,</sup><a href=" " data-type="journal-reference" data-value="Thomsen GN, Christoffersen MN, Lindegaard HM, Davidsen JR, Hartmeyer GN, Assing K, Mortz CG, Martin-Iguacel R, Møller MB, Kjeldsen AD, Havelund T, El Fassi D, Broesby-Olsen S, Maiborg M, Johansson SL, Andersen CL, Vestergaard H, Bjerrum OW, The multidisciplinary approach to eosinophilia. Front Oncol 2023;13: 1193730" data-value-piped="Thomsen GN, Christoffersen MN, Lindegaard HM, Davidsen JR, Hartmeyer GN, Assing K, Mortz CG, Martin-Iguacel R, Møller MB, Kjeldsen AD, Havelund T, El Fassi D, Broesby-Olsen S, Maiborg M, Johansson SL, Andersen CL, Vestergaard H, Bjerrum OW|The multidisciplinary approach to eosinophilia.|Front Oncol|2023|13|1193730|37274287" data-url="reference-link" data-pubmedid="37274287" title="Thomsen GN, Christoffersen MN, Lindegaard HM, Davidsen JR, Hartmeyer GN, Assing K, Mortz CG, Martin-Iguacel R, Møller MB, Kjeldsen AD, Havelund T, El Fassi D, Broesby-Olsen S, Maiborg M, Johansson SL, Andersen CL, Vestergaard H, Bjerrum OW, The multidisciplinary approach to eosinophilia. Front Oncol 2023;13: 1193730"><sup>5</sup></a></h3>
<ul>
    <li>Allergier (atopiske tilstande,&nbsp;<a href="~/link.aspx?_id=7E10960E2E0F419CB80F827BF0522708&amp;_z=z">astma</a>,&nbsp;<a href="~/link.aspx?_id=665D54AA280F4E7B8D2327EEC57D05D2&amp;_z=z">rhinitis allergica</a>,&nbsp;<a href="~/link.aspx?_id=5BFC45901FC7419C9EC49C4CE133AAE1&amp;_z=z">urticaria</a>)</li>
    <li>Parasit&aelig;re infektioner, og prim&aelig;rt
    <ul>
        <li>Indvoldsorme (<a href="~/link.aspx?_id=AB0C3251AE6A40159F0EF8076F11E8D7&amp;_z=z">Ancylostoma</a>,&nbsp;<a href="~/link.aspx?_id=49F9D2F9EF0B483E9574C9C3B903B3CE&amp;_z=z">Ascaris</a>,&nbsp;<a href="~/link.aspx?_id=3F4A1ECA499745AE86C44CF2FEDCDE50&amp;_z=z">Enterobius</a>,&nbsp;<a href="~/link.aspx?_id=AB0C3251AE6A40159F0EF8076F11E8D7&amp;_z=z">Necator</a>, Strongyloides, Toxocara, Trichinella,&nbsp;<a href="~/link.aspx?_id=EDB8A4F3C56D45D890767D8692481CA3&amp;_z=z">Trichuris</a>)</li>
        <li><a href="~/link.aspx?_id=9DDECEC94B184655A2AB6323D8DAB723&amp;_z=z">Filarier</a>&nbsp;(Brugia, Loa Loa, Onchocerca)</li>
        <li>Trematoder (Clonorchis, Fasciola, Paragonimus)</li>
    </ul>
    </li>
    <li>Andre infektionssygdomme (Scarlatina, Aspergillus, Coccidioide, tuberkulose, HIV)</li>
    <li>Hudsygdomme (<a href="~/link.aspx?_id=7D45D86461D841E490206F6B29E3D807&amp;_z=z">pemphigus vulgaris</a>,&nbsp;<a href="~/link.aspx?_id=49E3C4CBEF3646BA88407F0ECE74B3D3&amp;_z=z">dermatitis herpetiformis</a>,&nbsp;<a href="~/link.aspx?_id=C479A52E515D416DAA78BC1BF59ADB13&amp;_z=z">erythema multiforme</a>)</li>
    <li><a href="~/link.aspx?_id=086BE33B76FA418BAA7832723F89E1C0&amp;_z=z">Hypereosinofile syndromer</a>&nbsp;(L&ouml;efflers syndrom, tropisk eosinofili, dissemineret eosinofil kollagen sygdom) (mild &gt; 0,5 - 1,5&nbsp;x 10<sup>9</sup>/L, moderat 1,5 - 5,0&nbsp;x 10<sup>9</sup>/L, sv&aelig;r &gt; 5,0&nbsp;x 10<sup>9</sup>/L)</li>
    <li>Eosinifili med polyangiitis (tidligere&nbsp;Churg-Strauss syndrom)<a href=" " data-type="journal-reference" data-value="Emmi G, Bettiol A, Gelain E, Bajema IM, Berti A, Burns S, Cid MC, Cohen Tervaert JW, Cottin V, Durante E, Holle JU, Mahr AD, Del Pero MM, Marvisi C, Mills J, Moiseev S, Moosig F, Mukhtyar C, Neumann T, Olivotto I, Salvarani C, Seeliger B, Sinico RA, Taillé C, Terrier B, Venhoff N, Bertsias G, Guillevin L, Jayne DRW, Vaglio A, Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol 2023;19: 378-393" data-value-piped="Emmi G, Bettiol A, Gelain E, Bajema IM, Berti A, Burns S, Cid MC, Cohen Tervaert JW, Cottin V, Durante E, Holle JU, Mahr AD, Del Pero MM, Marvisi C, Mills J, Moiseev S, Moosig F, Mukhtyar C, Neumann T, Olivotto I, Salvarani C, Seeliger B, Sinico RA, Taillé C, Terrier B, Venhoff N, Bertsias G, Guillevin L, Jayne DRW, Vaglio A|Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis.|Nat Rev Rheumatol|2023|19|378-393|37161084" data-url="reference-link" data-pubmedid="37161084" title="Emmi G, Bettiol A, Gelain E, Bajema IM, Berti A, Burns S, Cid MC, Cohen Tervaert JW, Cottin V, Durante E, Holle JU, Mahr AD, Del Pero MM, Marvisi C, Mills J, Moiseev S, Moosig F, Mukhtyar C, Neumann T, Olivotto I, Salvarani C, Seeliger B, Sinico RA, Taillé C, Terrier B, Venhoff N, Bertsias G, Guillevin L, Jayne DRW, Vaglio A, Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol 2023;19: 378-393"><sup>6</sup></a></li>
    <li>Maligne sygdomme (<a href="~/link.aspx?_id=D203C807E8664DBC85CF0708A954B5A3&amp;_z=z">kronisk myeloid leuk&aelig;mi</a>, eosinofil leuk&aelig;mi,&nbsp;<a href="~/link.aspx?_id=17C7F13511584F368A3FC390D88772CD&amp;_z=z">Hodgkins sygdom</a>&nbsp;og andre lymfomer, diverse metastaserende cancere)</li>
    <li>Andet (<a href="~/link.aspx?_id=C7CF5C6B14864D8F8A6E93F35C2DC1A0&amp;_z=z">polyarteritis nodosa</a>, tryptofanbetinget eosinofili-myalgi, famil&aelig;r eosinofili)</li>
    <li>Reaktion p&aring; medikamenter, kan v&aelig;re mild med blot lidt hudaffektion til alvorlig reaktion med p&aring;virkning af viscerale organer (DRESS - Drug Reaction with Eosinophilia and Systemic Symptoms). Set ved behandling med&nbsp;allopurinol, sulfasalazine, visse antibiotika (beta-lactam antibiotika, minocyclin, dapson, sulfamethoxazol, vancomycin), antiepileptika (lamotrigin, valproat, carbamazepin, phenobarbital, phenytoin), antiretrovirale medikamenter (abacavir, nevirapine, raltegravir, efavirenz)</li>
    <li>Ingen klinisk betydning (sj&aelig;ldent)</li>
    <li>Eosinofili kan v&aelig;re frav&aelig;rende (maskeret) ved samtidig behandling med glukokortikoider eller aktuel eller nyligt overst&aring;et bakteriel infektion</li>
</ul>
<h3>Lave v&aelig;rdier (eosinopeni)</h3>
<ul>
    <li>Behandling med glukokortikoider eller&nbsp;<a href="~/link.aspx?_id=FFBDC4480D764006ABF132B5C9D6641C&amp;_z=z">Cushings syndrom</a></li>
    <li>Akutte bakterielle infektioner med neutrocytose og udtalt venstreforskydning</li>
</ul>
<h2>Fejlkilder (og kilder til normal variation)</h2>
<ul>
    <li>Kraftig fysisk aktivitet i timerne f&oslash;r blodpr&oslash;vetagning kan &oslash;ge antallet</li>
    <li>Maskeret eosinofili pga. behandling med glukokortikoider eller aktuel eller nyligt overst&aring;et bakteriel infektion</li>
</ul>
<h2>Biokemisk baggrund</h2>
<ul>
    <li>Produceres i knoglemarven ved stimulation af IL-5, IL-3 and GM-CSF</li>
    <li>Fra knoglemarven migrerer de til blodbanen, hvorfra de elimineres af makrofagsystemet eller migrerer ud i forskellige v&aelig;v, s&aelig;rligt i gastrointestinal kanalen, uterus, m&aelig;lkekirtler og thymus</li>
    <li>Har en halveringstid 8 - 18 timer i blodbanen, ukendt hvor l&aelig;nge eosinofilocytter overlever i v&aelig;vene</li>
    <li>Cellerne har forskellige typer granula, hvor is&aelig;r de sekund&aelig;re eosinofile granula er kendetegnende for eosinofilocytter</li>
    <li>Eosinofilocytter menes is&aelig;r at have en rolle i bek&aelig;mpelse af parasitter enten antistof-medieret eller ved frigivelse af toksiske stoffer fra de eosinophile granula&nbsp;</li>
</ul>
<h2>Pr&oslash;vetagning</h2>
<ul>
    <li>Som leukocyttyper</li>
</ul>
<h2>Referenceintervaller</h2>
<ul>
    <li>Der kan v&aelig;re forskelle i de angivne intervaller fra laboratorium til laboratorium</li>
    <li>Voksne og unge over 15 &aring;r: &lt; 0,5 x 10<sup>9</sup>/L</li>
    <li>B&oslash;rn under 2 m&aring;neder: &lt; 0,9 x 10<sup>9</sup>/L</li>
    <li>B&oslash;rn mellem 2 m&aring;neder&nbsp;og 15 &aring;r: &lt;0,5 x 10<sup>9</sup>/L</li>
    <li>Antallet svarer i alle tilf&aelig;lde typisk til 2-3 % af alle leukocytter</li>
</ul>
<h2>Patientinformation</h2>
<ul>
    <li><a href="~/link.aspx?_id=16F4CD4F60D24C838E5FB7E27F8A200A&amp;_z=z">B-leukocytter (hvide blodlegemer)</a></li>
</ul>
<h2>NPU-koder og -navne</h2>
<ul>
    <li>NPU17562</li>
    <li>NPU01933</li>
</ul>
<h3>Navne</h3>
<ul>
    <li><strong>Langt navn</strong>
    <ul>
        <li>B&mdash;Eosinophilocytter; antalk.(mikr.) = ? &times; 109/L</li>
        <li>B&mdash;Eosinophilocytter; antalk. = ? &times; 109/L</li>
    </ul>
    </li>
    <li><strong>Kort navn</strong>
    <ul>
        <li>Eosinofilocytter (mikr.);B</li>
        <li>Eosinofilocytter;B</li>
    </ul>
    </li>
</ul>]]></HtmlField>
      <HtmlField Name="Resume"><![CDATA[<h2>Resum&eacute;</h2>
<ul>
    <li>Analysen indg&aring;r i en leukocyttype-bestemmelse/differentialt&aelig;lling</li>
    <li>Is&aelig;r forh&oslash;jede v&aelig;rdier er relevante, og kan ses ved en r&aelig;kke forskellige sygdomme af varierende klinisk betydning</li>
    <li>Kan eksempelvis v&aelig;re tegn p&aring; infektion, allergisk reaktion, medikament-reaktion og malign sygdom</li>
</ul>]]></HtmlField>
      <LinkListField Name="Spot2">
        <LinkField linktype="internal">{99A85AFD-2F7A-4B5D-A1C9-C2701D5E7D30}</LinkField>
      </LinkListField>
      <TextField Name="DoctorsHandbookID">2965</TextField>
      <TextField Name="PageTitle">Eosinofile leukocytter</TextField>
      <TextField Name="NavigationTitle">Eosinofile leukocytter</TextField>
      <CheckBoxField Name="ShowInMenu">true</CheckBoxField>
      <CheckBoxField Name="ShowInContentField">true</CheckBoxField>
      <DateTimeField Name="RevisedDate">2024-07-24T11:33:00</DateTimeField>
      <LinkListField Name="Authors">
        <LinkField linktype="internal">{E3258509-7DFB-4092-BE9F-B584BD8A18BA}</LinkField>
        <LinkField linktype="internal">{FDEF4DBD-AAF0-4AF0-82F7-983F8710B93E}</LinkField>
      </LinkListField>
      <LinkListField Name="Organization">
        <LinkField linktype="internal">{CF77E8B9-9937-42B2-85DF-76B0F4E401F0}</LinkField>
      </LinkListField>
      <LinkListField Name="SearchAreaID">
        <LinkField linktype="internal">3</LinkField>
      </LinkListField>
      <TextField Name="Description">Eosinofil-antallet indgår i differentialtælling og er særligt relevant ved mistanke om allergiske sygdomme, parasitære infektioner, autoimmune sygdomme, vaskulitter og visse maligne sygdomme</TextField>
      <LinkListField Name="LHPHEditor">
        <LinkField linktype="internal">{C70DFB71-BE40-455A-BD6B-5AFF199797D9}</LinkField>
      </LinkListField>
      <TextField Name="__Updated by">sitecore\kack</TextField>
      <TextField Name="MetaKeywords">eosinofile granulocytter, eosinofile, Eosinofile leukocytter, eosinofilocytter</TextField>
      <LinkListField Name="InformationCategory">
        <LinkField linktype="internal">IC_3</LinkField>
      </LinkListField>
      <LinkListField Name="InformationType">
        <LinkField linktype="internal">7</LinkField>
      </LinkListField>
      <LinkListField Name="SearchTargetGroup">
        <LinkField linktype="internal">2</LinkField>
      </LinkListField>
    </Content>
    <Medias />
  </Item>
</Provider>

15.400 characters